| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
Today’s Big NewsSep 13, 2024 |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
| By James Waldron It’s a busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public. |
|
|
|
By Nick Paul Taylor The FDA should be more open and collaborative to unleash a surge in approvals of rare disease drugs, according to a report by the National Academies of Sciences, Engineering, and Medicine. |
By Darren Incorvaia In the wake of a second quarter that saw revenues decline by 3.2%, contract research organization Charles River Laboratories is laying off 3% of its workforce, a spokesperson confirmed to Fierce Biotech in an emailed statement. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
|
Partner with us for vaccine manufacturing that expertly integrates novel analytical and process-related technologies with your program's unique needs, ensuring efficient tech transfer and rapid scaling. Grow with us. 
|
|
By Darren Incorvaia,Zoey Becker After 25 years at Johnson & Johnson and 30 in the industry, Lucinda Warren is moving on to new pastures at Cue Biopharma as its first chief business officer. |
By James Waldron Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C. |
By Nick Paul Taylor Neurocrine Biosciences’ schizophrenia program pivot has failed. The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of luvadaxistat. |
By Conor Hale The agency’s clearance marks its first for a piece of over-the-counter hearing aid software—and hails the long-awaited entry of the consumer tech giant to the sector. |
By Kevin Dunleavy Using the ESMO Magnitude of Clinical Benefit Scale, a group of Harvard researchers has scored companies according to the value of the cancer drugs they have brought to the market. Among the standout drugmakers in the analysis were Novartis, Daiichi Sankyo and AstraZeneca. |
By Angus Liu Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The BIOSECURE Act sailed through a full House vote despite some objections. Candid Therapeutics amassed $370 million in series A funds with two T-cell engagers licensed from China. And more. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. |
|
|---|
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
